Immunotherapy | Tumor

CURE’s immunotherapy page features the latest cancer news and updates on immunotherapy Through articles, videos, podcasts, and more, CURE brings readers the insights of experts, cancer survivors, patients, and advocates to ensure everyone is up to date in immunotherapy.

Mediterranean Diet May Boost Immunotherapy Outcomes

March 27th 2023

Patients with advanced melanoma who followed the Mediterranean diet tended to have improved responses to immunotherapy treatment, recent research showed.

Keytruda Meets Trial Goals for Non-Small Cell Lung Cancer Treatment

March 9th 2023

Keytruda plus chemotherapy before surgery and as single agent after improved outcomes for patients with resectable non-small cell lung cancer.

FDA Agrees to Review Opdivo for Post-Surgical Melanoma Treatment

March 8th 2023

The Food and Drug Administration accepted a supplemental Biologics License Application for Opdivo to treat stage 2B or C, fully resected melanoma.

Immunotherapy Effectiveness Tied to Particular Cell Activity

March 7th 2023

Patients who do not respond to immunotherapy have reduced CD5 activity in their tumors, opening the door for more effective immunotherapy treatments.

Keytruda Misses Outcomes in Two Clinical Trials

March 1st 2023

One of the trials investigating Keytruda has been discontinued because the drug did not significantly improve outcomes in patients with prostate cancer.

A Better Treatment May Exist for Immunotherapy-Related Heart Problems

February 23rd 2023

Standard corticosteroid use may not be the best treatment for patients with cancer who experience immunotherapy-related heart issues, research showed.

Keytruda Approval Offers ‘Another Form of Insurance’ to Keep Lung Cancer From Returning

February 8th 2023

An expert discussed the recent approval of Keytruda for non-small cell lung cancer, and what patients with the disease need to know about the newly approved regimen.

Biomarker Algorithm May Predict Immunotherapy Outcomes Across Cancer Types

February 7th 2023

A new tool may identify more patients with cancer who can benefit from immunotherapy.

Despite Rapid Increase in Immunotherapy Use for Lung Cancer, Survival Benefit for Older Patients Is Modest

February 2nd 2023

Since 2015, the use of immunotherapies has increased for both young and older patients, but the survival benefit is more evident in younger patients, findings demonstrated.

Low-Dose Immunotherapy Boosts Survival in Head and Neck Cancer

January 25th 2023

Opdivo — even when given in a low dose — was shown to improve outcomes in patients with advanced head and neck squamous cell carcinoma, highlighting a new option for patients who cannot receive the full dose.

Researchers Are ‘Building Up the Wall of Evidence’ to Support Cancer Vaccines in the Future

January 25th 2023

As more news is released about studies assessing cancer vaccines, one expert explains what this may mean for patients in the future.

Opdivo Improves Time to Disease Recurrence in Stage 2B and 2C Skin Cancer

October 20th 2022

When given after surgery, Opdivo improved relapse-free survival compared to placebo in patients with stage 2B or 2C skin cancer, according to recent results from the CheckMate-76K clinical trial.

Investigational Tumor-Infiltrating Lymphocyte Therapy in Solid Tumors

September 19th 2022

Injectable Tecentriq Is Efficacious, Reduces Treatment Time for Lung Cancer

August 2nd 2022

Subcutaneous (injectable) Tecentriq had similar movement throughout the body, while saving on treatment time compared to intravenous administration of the drug in a group of patients with non-small cell lung cancer.

In Recent Decades, Immunotherapy Extended Advanced Melanoma Survival from Months to Years

July 11th 2022

Thanks to the FDA approval of immunotherapy agents, the average survival for patients for stage 4 melanoma has drastically increased over the past 20 years, an expert explained.

FDA Approves Kymriah for Relapsed/Refractory Follicular Lymphoma

May 31st 2022

Kymriah, a CAR-T cell therapy, was approved by the Food and Drug Administration for the treatment of patients with pretreated, relapsed/refractory follicular lymphoma.

Skin Cancer Diagnosis, Older Age May Be Associated With Increased Risk for Rare Skin Condition from Immunotherapy Treatment

April 19th 2022

Patients within the study who developed the rare skin condition were more likely to experience better tumor responses than those who did not develop the side effect.

Invading Cancer Cells With Immunotherapy Combinations

March 16th 2022

Recent research has demonstrated the ability of immunotherapy combinations to target advanced melanoma.

Immunotherapy Side Effects: ‘No Organ System Potentially Unaffected’

November 23rd 2021

Immunotherapy side effects are a different than those of chemotherapy and other cancer treatments. Patients should know when to seek emergency care and what to communicate to clinicians.

The 'Promise' of Precision Medicine: Making Incurable Cancers Into Chronic Diseases

October 1st 2021

One oncologist highlighted the knowledge base of the immunotherapy and targeted therapy and how they interact with cancer cells.

Further Evaluating Biomarkers May Help to Better Interpret Which Patients Are Eligible For Immunotherapy

September 29th 2021

Getting rid of the "blanket statement" and looking deeper into genetics may allow patients with cancer who are older than 60 years to become eligible for immunotherapy, highlighting the importance of further research on the topic.

The Impact of Immunotherapy

June 25th 2021

Thanks to ongoing research and clinical trials, it seems that there are always new immunotherapies emerging.

Bispecific Antibodies Wage a Two-Pronged Attack on Tumors

June 16th 2021

BiTE therapy could lead to better ways to target the immune system, while minimizing the chance of resistance.

Intralesional Therapies Help Bridge the Gap Between Improved Results and Less Toxicity

June 15th 2021

First immunotherapy, intralesional therapy, is making a comeback and producing durable remissions for a subgroup of patients with cancer.

Tecentriq Significantly Improves Survival Outcome in Patients with Early-Stage Non-Small Cell Lung Cancer

May 21st 2021

The data, according to an expert, show that treatment with Tecentriq could delay disease progression to an advanced stage, as well as the need for more aggressive therapy.

Immunotherapy Could 'Provide A Whole New Realm' For Patients with Myeloma

May 14th 2021

New advances in research around immunotherapies for patients with myeloma are on the horizon, according to an expert from the HealthTree Foundation & Myeloma Crowd.

Our Microbiome: A Reflection of Ourselves?

May 9th 2021

Sophisticated analyses can predict which gut microbiome profile may lead to better outcomes to immunotherapy for patients with advanced melanoma.

Follow Your Gut: Advances in Understanding Microbiomes Are Transforming Cancer Care

April 28th 2021

The gut microbiome plays an important role in how patients may respond to cancer treatments, and researchers are learning more about ways to alter it to benefit treatment outcomes.

Targeting a Specific Genetic Mutation May Change Treatment Landscape for Non-Small Cell Lung Cancer

April 21st 2021

Patients with non-small cell lung cancer and a KRAS G12C genetic mutation may benefit from treatment with an inhibitor targeting that mutation, although more research is needed to learn why more patients are not responding to the drug.

Cell-Based Therapies May ‘Level the Playing Field’ in Non-Small Cell Lung Cancer

April 20th 2021

Even with all the recent advances in targeted therapies and immunotherapy drugs, patients with non-small cell lung cancer still need more treatment options. Although it’s early, cell-based therapies have shown some promise, with more research underway.